Project Grant HT9425261E118
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $350K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $817,496 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award funds research to investigate the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $5.47M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2029. The award funds research aimed at targeting ganglioside GD2 to overcome chemotherapy resistance in triple-negative breast cancer. This research initiative represents translational and clinical investigation...
- Federal Project Grant Summary The University of Texas MD Anderson Cancer Center received a $347,581 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on ovarian cancer dormancy induced by metabolic alterations. The two-year award, effective June 1, 2026 through May 31, 2028, supports basic and translational research designed to advance understanding of metabolic mechanisms that contribute to cancer...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $893,525 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award funds research titled "Targeting Neuronal Mimicry in SMARCB1-Deficient Renal Medullary Carcinoma Treatment," which investigates novel therapeutic approaches to address renal medullary...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $414,472 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award supports research targeting neuronal mimicry in SMARCB1-deficient renal medullary carcinoma (RMC) treatment. This three-year initiative delivers translational research and therapeutic development services...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $735,751 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025, through August 31, 2028. The award supports research and development activities focused on combining TROP2-directed chimeric antigen receptor natural killer (CAR-NK) cells with HIF2A (hypoxia-inducible factor 2-alpha) inhibition as an...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1.35 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the three-year period from October 1, 2025, through September 30, 2028. The award funds research focused on building T-cell products for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNST) through antigen discovery and...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1,431,215 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded October 1, 2025, with a completion date of September 30, 2028. The award funds research focused on building T-cell products for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNST) through antigen discovery and...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $489,767 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective October 1, 2025, through September 30, 2028. The award supports research titled "Building T-Cell Products in NF1-Associated MPNST Through Antigen Discovery and Epigenome Targeting," which addresses the development of therapeutic T-cell immunotherapy...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $932,350 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 15, 2025, through August 14, 2028. The grant supports the development and evaluation of an in situ tumor vaccine designed to stimulate antitumor immunity against breast cancer. This three-year research initiative will be conducted at MD...